• FluTrackers.com Inc. does not provide medical advice. Information on this web site is collected from various internet resources, and the FluTrackers board of directors makes no warranty to the safety, efficacy, correctness or completeness of the information posted on this site by any author or poster. The information collated here is for instructional and/or discussion purposes only and is NOT intended to diagnose or treat any disease, illness, or other medical condition. Every individual reader or poster should seek advice from their personal physician/healthcare practitioner before considering or using any interventions that are discussed on this website. By continuing to access this website you agree to consult your personal physican before using any interventions posted on this website, and you agree to hold harmless FluTrackers.com Inc., the board of directors, the members, and all authors and posters for any effects from use of any medication, supplement, vitamin or other substance, device, intervention, etc. mentioned in posts on this website, or other internet venues referenced in posts on this website.
  • We are not asking for any donations. Do not donate to any entity who says they are raising funds for us.

J Med Virol . Lymphopenia and lung complications in patients with coronavirus disease-2019 (COVID-19): A retrospective study based on clinical data

tetano

Editor, Senior Moderator
J Med Virol


. 2021 May 4.
doi: 10.1002/jmv.27060. Online ahead of print.
Lymphopenia and lung complications in patients with coronavirus disease-2019 (COVID-19): A retrospective study based on clinical data


Ehsan Zaboli[SUP] 1 [/SUP], Hadi Majidi[SUP] 2 [/SUP], Reza Alizadeh-Navaei[SUP] 1 [/SUP], Akbar Hedayatizadeh-Omran[SUP] 1 [/SUP], Hossein Asgarian-Omran[SUP] 1 [/SUP], Laleh Vahedi Larijani[SUP] 3 [/SUP], Vahid Khodaverdi[SUP] 1 [/SUP], Omolbanin Amjadi



Affiliations

Abstract

Background: A rapid outbreak of novel coronavirus, COVID-19, made it a global pandemic. This study focused on the possible association between lymphopenia and Computed tomography (CT) scan features and COVID-19 patient mortality.
Method: The clinical data of 596 COVID-19 patients were collected from February 2020 to September 2020. The patients' serological survey and CT scan features were retrospectively explored.
Results: The median age of the patients was 56.7?16.4 years old. Lung involvement was more than 50% in 214 COVID-19 patients (35.9%). The average blood lymphocyte percentage was 20.35 ?10.16 (normal range 20- 50%). While the levels of C-reactive protein (CRP), and erythrocyte sedimentation rate (ESR), were high in more than 80% of COVID-19 patients; CRP, ESR, and platelet-to-lymphocyte ratio (PLR) may not indicate the in-hospital mortality of COVID-19. Patients with severe lung involvement and lymphopenia were found to be significantly associated with increased odds of death (odds ratio [OR], 9.24; 95% confidence interval [95 CI%], 4.32- 19.78). These results indicated that lymphopenia <20% along with pulmonary involvement >50% impose a multiplicative effect on the risk of mortality. The in-hospital mortality rate of this group was significantly higher than other COVID-19 hospitalized cases. Furthermore, they meaningfully experienced a prolonged stay in the hospital (P= 0.00).
Conclusion: The Lymphocyte count less than 20% and chest CT scan findings with more than 50% involvement might be related to the patient's mortality. It could act as laboratory and clinical indicators of disease severity, mortality, and outcome. This article is protected by copyright. All rights reserved.

Keywords: COVID-19; Lung CT scan; Lymphopenia; Mortality.
 
Back
Top Bottom